We found that pnpla3 ASO treatment decreased hepatic DAG content and protected rats from lipid-induced hepatic insulin resistance, which could be attributed to decreased DAG-mediated PKCε activation.1, 41 In addition, we demonstrated that pnpla3 plays a lipogenic role through fatty acid esterification at the level of AGPAT in vivo. This evidence concerns the gene PNPLA3 and Insulin resistance.